Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Zai Lab Approved to Launch Fc Receptor Agonist for Myasthenia Gravis Patients

publication date: Jul 3, 2023

Shanghai Zai Lab was approved to launch Vyvgart® in China as an add-on to standard of care treatment for generalized myasthenia gravis in adult patients who are anti-acetylcholine receptor antibody positive. Vyvgart® (efgartigimod alfa injection) is a first-in-class neonatal Fc receptor (FcRn) antagonist. Two years ago, Zai acquired Vyvgart® from Amsterdam’s argenx SE in a $175 million deal. Zai said it will now work with government officials to include the drug in China’s National Reimbursement Drug List. More details....

Stock Symbols: (NSDQ: ZLAB; HK: 9688) (Euronext/NSDQ: ARGX)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here


BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here


Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here